Pharmaceuticals Financial News

Subscribe to enjoy similar stories. New Delhi: India has revised rules for opening retail outlets under a government scheme to sell high-quality generic drugs at affordable prices, mandating a minimum distance of 500 meters between stores in major urban areas, according to two officials and a document reviewed by Mint. This decision replaces the guidelines issued in September, and seeks to balance the scheme’s rapid expansion with the financial health of Pradhan Mantri Bharatiya Janaushadhi Kendras.

Earlier this month, the Delhi high court, in separate judgements, allowed Dr Reddy’s Laboratories and Sun Pharmaceutical Industries to manufacture and export generic semaglutide to non-patent-holding countries. However, both companies cannot sell the drug domestically until innovator Novo Nordisk loses its patent-exclusivity rights in the country in March 2026.While experts said the move by Dr Reddy’s and Sun Pharma is to grab an early-mover advantage in selling the blockbuster weight-loss drug, the companies won’t be the first to enter non-patented markets.

Subscribe to enjoy similar stories. New Delhi: As the India-Oman free trade agreement (FTA) is set to be signed on Thursday during Prime Minister Narendra Modi’s visit to Muscat, the deal is being positioned as a key pillar of India’s expanding economic and strategic engagement with the Gulf, even as its immediate trade upside remains measured by the size of Oman’s market. The Comprehensive Economic Partnership Agreement (CEPA) will be the final stop of the Prime Minister’s three-nation tour, which included Jordan and Ethiopia.

Subscribe to enjoy similar stories. India Inc. is expected to roll out an average increment of 8.5-9.5% in the upcoming appraisal cycle, as companies calculate the impact of the new labour code and almost-stagnant inflation.

For pharmaceutical firms, watching lucrative patents on their top-selling drugs expire has long been part of the business cycle. There’s enormous pressure to find ways of covering the shortfall. For the first time, China has something to offer.

Subscribe to enjoy similar stories. French pharmaceutical group Servier is sharpening its India strategy with a string of new oncology launches focused on rare cancers, plans for local manufacturing of active ingredients, and a move to bring global clinical trials to the country for the first time. The shift marks a significant elevation of India in Servier’s global priorities, aligning it almost in step with launches in the western markets.

Subscribe to enjoy similar stories. India plans to get its drug regulatory system audited and rated by the World Health Organization (WHO) to detect specific strengths and weaknesses that will help to make it fool proof, according to four officials and a document reviewed by Mint. The move comes after multiple instances of drug safety related incidents in the country as well as export markets raised serious questions on the quality of medicines made in India, often referred to as ‘pharmacy of the world’.

Subscribe to enjoy similar stories. Mumbai: Kuala Lumpur-based private equity firm Creador has acquired a 7% stake in La Renon Healthcare from the promoter and existing investor Peak XV Partners for an undisclosed sum, the companies said in a statement on Monday. Creador’s purchase of shares from Peak XV comes about a decade after the venture capital firm first invested in the company.

Subscribe to enjoy similar stories. Dr Reddy’s Laboratories Ltd (DRL) received a shot in the arm on 2 December, when the Delhi High Court allowed it to export the weight-loss drug semaglutide, which is set to become patent-free in several countries including Canada, China and Brazil from January 2026. While the order restricts sales of semaglutide in India until it goes off-patent here in March, this window will help DRL prepare for the domestic launch.

The 27-country bloc faces 25 per cent import tariffs on steel and aluminium and cars and 'reciprocal' tariffs of 20 per cent from Wednesday for almost all other goods. President Trump's tariffs cover some 70 per cent of the EU's exports to the United States — worth in total 532 billion euros ($585 billion) last year — with likely duties on copper, pharmaceuticals, semiconductors and timber still to come. When Trump hit steel and aluminium imports with a 25 percent tariff in March, the EU decided on «an eye for an eye» approach. «We will react in areas where it hurts the United States,» a senior EU official said. Officials have previously said the EU will target goods from politically important US states, including soybeans produced in Louisiana, the home of US Speaker Mike Johnson, who pushes Trump's agenda in Congress. The is happening even though, President Trump's one of the closest advisers billionaire Elon Musk told Italy League leader Matteo Salvini on Saturday that he hoped in the future the US and Europe could create «a very close, stronger partnership» and reach a «zero-tariff zone.» Musk spoke to Salvini in a video conference during the League's congress in Florence. Salvini is the leader of the far-right, anti-migrant League party and vice premier of the Italian conservative government led by Premier Giorgia Meloni.

reciprocal tariffs by the US on other competing nations raises the possibility of increased dumping by those nations in India, as well as in other export markets, which could negatively impact certain sectors, CareEdge Ratings said in a report. According to the report ' Sectoral Impact of US Reciprocal Tariff: Neutral to Negative, ' the expected direct impact of US reciprocal tariffs would vary, with no impact expected on pharmaceuticals since they are exempt from reciprocal tariffs for now. According to the rating agency, the impact is expected to be largely neutral for electronics, textiles, agricultural products, chemicals, and automobiles and parts. At the same time, it would be negative for gems and jewellery. During 2023-24, India's aggregate merchandise exports to the US stood at USD 77.5 billion compared to its imports from the US at USD 42.2 billion. Out of India's total exports to the US, the sectors in descending order of value are electronics, textiles, pharmaceuticals, gems and jewellery, agricultural products, chemicals and automobiles and parts.

“We have to be patient. Trade pacts do not happen overnight. It is a careful and steady process. Things are analysed carefully,” an official said on the condition of anonymity, adding that a slight impact on demand in the US could be a little challenging. India has “emerged a winner” following the reciprocal tariffs imposed by the United States, officials said, pointing out that the country has a first mover advantage compared to its competitors owing to of the Bilateral Trade Agreement (BTA) that the two are negotiating and because Indian exporters are better positioned to deal with the additional US tariffs. They said the country will take all measures within the World Trade Organization (WTO) framework to check dumping of goods from countries such as China which have been slapped with steeper tariffs. “The government is there to protect domestic industry from any possibility of dumping of goods in such a situation,” the official added. While the US has imposed 26% reciprocal tariffs on India, it has levied 34% additional import duties on China. India is also likely to gain from the US-China trade war, according to officials.

reciprocal tariffs imposed by the US and has a first mover advantage as compared to other countries because of the Bilateral Trade Agreement (BTA) that the two are negotiating, officials said, adding that Indian exporters are better positioned to deal with the additional US tariffs as compared to their competitors. The country, they said, will take all measures to check dumping of goods from China as Beijing is slapped with steeper tariffs and work within the World Trade Organization (WTO) framework to prevent the dumping of excess capacity into its markets by countries hit by high US tariffs. “The government is there to protect domestic industry from any possibility of dumping of goods in such a situation,” said an official. New Delhi is also exploring measures to protect sensitive sectors like dairy and agriculture amid the trade war. While the reciprocal tariffs on India are 26%, those on China are 34%. India is also likely to gain from the US-China trade war.

Subscribe to enjoy similar stories. Mumbai: A spell of weakness in Asian markets spilled into Indian equities on Friday, sparking a sell-off that swept across sectors. Indian markets that averted a steep fall a day earlier plunged 1.5%, as fears of a US recession and its consequences grew.

Automobile and ancillaries

Rahul Gandhi on Thursday raised the issue of reciprocal tariffs imposed by US President Donald Trump in the House on Thursday and said it will «completely devastate» the Indian economy. Gandhi raised the issue during Zero Hour and said, «Our ally has suddenly decided to impose a 26% tariff, which is going to completely devastate our economy — our auto industry, pharmaceutical industry, and agriculture are all in line.» Trump on Wednesday announced new reciprocal tariffs on several countries, including India, saying that the US has been «looted, pillaged, raped, plundered» by other nations. While the US announcement lists 26% as the tariff levied on India, other documents, including those received by the ministry, show that the rate is actually 27%. Gandhi also claimed that China had taken over 4,000 square kilometres of Indian territory and demanded answers from the government over these issues.

Rajshree Sugars & Chemicals Ltd.(up 6.72%), Kothari Sugars & Chemicals Ltd.(up 3.49%), Rana Sugars Ltd.(up 2.98%), Sakthi Sugars Ltd.(up 2.94%), Bannari Amman Sugars Ltd.(up 2.91%), KCP Sugar & Industries Corporation Ltd.(up 2.47%), Vishwaraj Sugar Industries Ltd.(up 2.36%), Balrampur Chini Mills Ltd.(up 2.28%), Dalmia Bharat Sugar and Industries Ltd.(up 2.16%) and EID Parry(India)Ltd.(up 1.92%) stood among the top gainers.

Mangalore Chemicals & Fertilizers Ltd.(up 9.43%), Paradeep Phosphates Ltd.(up 5.26%), Nagarjuna Fertilizers and Chemicals Ltd.(up 4.94%), Aries Agro Ltd.(up 4.75%), Agro Phos India Ltd.(up 3.57%), Madras Fertilizers Ltd.(up 3.15%), Zuari Agro Chemicals Ltd.(up 2.75%), Sikko Industries Ltd.(up 2.63%), Gujarat State Fertilizer & Chemicals Ltd.(up 2.13%) and Rashtriya Chemicals & Fertilizers Ltd.(up 1.88%) stood among the top gainers.

Subscribe to enjoy similar stories. US President Donald Trump announced sweeping reciprocal tariffs on its trading partners on 2 April, a move aimed at reducing the country’s dependency on foreign products amid its ballooning trade deficit. Trump announced a 26% tariff on imports from India, effective 9 April.

Indian exports unviable, while UBS labeled it a “negative event” for the market, citing a direct threat to GDP. While the across-the-board duties threaten to make some exports unviable, the exemption for pharmaceuticals—India’s largest export category to the US—provided a rare bright spot, triggering a rally in Indian drugmaker stocks on Thursday.

Thyrocare took only 10 minutes. Finally, in 2021, he exited his company in a mere 60 seconds. His philosophy? 'Decide first, discuss later". His journey proves that speed and conviction in decision-making can shape extraordinary success. Dr. Arokiaswamy Velumani, the founder of Thyrocare, built a billion-dollar enterprise from humble beginnings. Born in a small village in Tamil Nadu to a family of landless farmer and despite severe financial struggles, he became the first graduate from his village in 1978, marking the start of an extraordinary journey.